Product
Sing2016 M2SR H3N2 influenza vaccine
1 clinical trial
1 indication
Indication
InfluenzaClinical trial
Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old.Status: Completed, Estimated PCD: 2021-11-30